Table 1 Demographic characteristics (Commercial/Medicare and Medicaid)
From: Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates
Commercial/Medicare | Medicaid | |||
|---|---|---|---|---|
Raloxifene | Bisphosphonates | Raloxifene | Bisphosphonates | |
(N = 17,983) | (N = 79,891) | (N = 11,504) | (N = 59,881) | |
Age (Mean, std.)* | 62.2 (9.0) | 64.2 (10.7) | 69.3 (11.1) | 71.8 (10.8) |
Age group* | % | % | % | % |
45–64 | 69.0 | 59.8 | 32.3 | 23.7 |
65–74 | 19.5* | 20.2* | 34.2* | 34.0* |
75 and over | 11.5 | 20.0 | 33.5 | 42.2 |
Race * | ||||
White | --- | --- | 33.9 | 39.9 |
African American | --- | --- | 5.3 | 6.2 |
Hispanic/Latino | --- | --- | 15.1 | 17.2 |
Asian | --- | --- | 29.6 | 21.4 |
Other | --- | --- | 16.1 | 15.3 |
Medicare* | 26.6 | 36.7 | --- | --- |
Location* | ||||
North East | 7.3 | 10.7 | --- | --- |
North Central | 34.0 | 32.9 | --- | --- |
South | 46.1 | 38.5 | --- | --- |
West | 12.2 | 17.7 | --- | --- |
Unknown | 0.4 | 0.3 | --- | --- |
Urban residence* | 72.1 | 78.2 | 89.4 | 90.7 |
Insurance type* 1 | ||||
Indemnity | 34.5 | 39.3 | 82.3 | 82.3 |
PPO | 44.7 | 40.8 | --- | --- |
Other | 20.8 | 19.9 | 17.7 | 17.7 |
Provider specialty* | ||||
Specialist2 | 18.8 | 16.8 | 6.5 | 4.9 |